StreetAlpha.app
Home › Stocks › RDY

DR Reddys Laboratories Ltd (RDY)

Healthcare
$14.80
▲ +0.68%
LAST CLOSE · NOV 17

Dr. Reddy's makes generic medicines, active pharmaceutical ingredients and consumer healthcare products. It last closed at $14.80 on Nov 17, up 0.68% on the day. RDY reports earnings on Fri, Jan 22, 2027. In the past 30 days there were 1 dark pool print totaling $3.0M, the largest $3.0M.

AI Auto Pilots
Is RDY in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$3.8B
+13.8% vs a year ago
Net income
$663.0M
−0.7% vs a year ago
Free cash flow
$223.0M
5.9% margin
Gross margin
58.5%
$2.2B gross profit
Balance sheet
Cash & equivalents
$172.0M
At Mar 31
Shareholder equity
$3.9B
CEOG. V. Prasad
Fiscal year endsMarch
ExchangeNYSE
Financials history
FY2021: $2.6B$2.6BFY2021FY2022: $2.8B$2.8BFY2022FY2023: $3.0B$3.0BFY2023FY2024: $3.4B$3.4BFY2024FY2025: $3.8B$3.8BFY2025

From RDY's SEC filings, latest 20-F for the period ending Mar 31, 2025 (filed May 29). Per share figures are left out because the US listing can represent a different number of shares.

Next report
Jan 22
2027 · Time not announced
Consensus EPS forecast
$0.15
$952.7M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated RDY in the past 90 days, not enough for a consensus
Average 12-month target
$1450.00
▲ 9697.3% upside

Based on 1 analyst who set a price target on RDY in the past 90 days. The average target is $1450.00, with a high of $1450.00 and a low of $1450.00, compared with the last close of $14.80.

Low $1450.00Avg $1450.00High $1450.00
Blue marker: last close $14.80
Highest target$1450.00
Average target$1450.00
Lowest target$1450.00
Latest rating changes
CitigroupUpgrade
Sep 29Buy$1450
DateFirmActionRatingPrice target
Sep 29CitigroupUpgradeBuy$1450
Loading…

Technical Analysis

RDY · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 3% above its 20 day and 11% above its 50 day average. It is 10% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 70), near overbought. The nearest support is the Pivot S1 at $14.73, and the nearest resistance the Pivot at $14.83.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNear overbought
VolatilityNormal, 1.9%/day
Key levels
$15.6752 week high+5.9%
$15.07Swing high (Nov 9)+1.8%
$14.91Pivot R1+0.7%
$14.83Pivot+0.2%
$14.80Last close
$14.73Pivot S1−0.5%
$14.3020 day average−3.4%
$13.95Swing low (Jul 1)−5.7%
$13.29200 day average−10.2%
$13.1650 day average−11.1%
$12.85100 day average−13.2%
$11.3652 week low−23.2%
Indicators
RSI (14)69.72Strong, overbought above 70Neutral
MACD0.50Below its signal lineBearish
Stochastic74.6Middle of its rangeNeutral
ADX (14)40.7Strong uptrend
Williams %R-26.8Oversold below −80, overbought above −20Neutral
CCI (20)73.6Oversold below −100, overbought above 100Neutral
Rate of change+3.4%Change over 10 sessionsBullish
ATR (14)$0.28Typical daily range, 1.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for RDY

What happened before

See how RDY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RDY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RDY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RDY in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$3.0M
Largest print
$3.0M
Loading…

RDY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼87 buying vs 131 selling
  • ▼Shares held by funds -4.8%
  • ▼Funds holding -7
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding232239−2.9%
In funds' top 10110.0%
Held by funds–––
New / increased25 / 6228 / 77−17.1%
Reduced / sold out100 / 3195 / 37−0.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RDY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RDY is in one of them and how their past RDY trades turned out.

RDY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RDY in an article yet. Here's the latest on the wider market.

About DR Reddys Laboratories

Dr. Reddy's is a pharmaceutical company based in Hyderabad, India. It makes and sells generic medicines, both branded and unbranded, along with biosimilars and consumer healthcare products. It also manufactures active pharmaceutical ingredients, the core ingredients used in finished medicines, and offers contract research and manufacturing services to other drug companies. Its key markets include the United States, India, Russia, other former Soviet countries and Europe.

Headquarters
Hyderabad
Founded
1984